abstract |
The present invention relates to novel inhibitors of prolyl endopeptidase of formula (1): [Chemical 1] (Wherein I, A, X, Y and Z are specified in the specification). The compounds are useful for the treatment of diseases such as mild cognitive impairment (MCI), Alzheimer's disease, Down's syndrome, Parkinson's disease and Huntington's chorea. |